CMMB News and Press, Chemomab Therapeutics Ltd. From 04/24/24

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will report its first quarte...

—Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic and Vascular Manifestations of SSc— TEL AVIV, Israel, April 18, 2024 (G...

—“Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis” Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development— TEL AVIV, Israel, April 02, 2024 (GLOBE ...

—European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis— —Further Extends Protections Afforded by CM-101 Composition of Matter and Methods and Use Patents That Hav...

2024-03-07 12:53:15 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chemomab Therapeutics (NASDAQ: CMMB ) just reported results for the fourth quarter of 2023. Chemomab Therapeutics reported earnings per share of -26 cents. The company...

2024-03-07 07:55:10 ET More on Chemomab Therapeutics Seeking Alpha’s Quant Rating on Chemomab Therapeutics Historical earnings data for Chemomab Therapeutics Financial information for Chemomab Therapeutics Read the full article on Seeking Alpha ...

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update PR Newswire ─Accelerated Phase 2 CM-101 PSC Trial Timeline with Topline 15-Week Data Now Planned for Midyear 2024 and Topline Open Label Data Expe...

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference PR Newswire TEL AVIV, Israel , March 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therap...

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases PR Newswire —CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topl...